Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8396MR)

This product GTTS-WQ8396MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Diffuse Large B Cell Lymphoma (DLBCL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ8396MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15834MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ11841MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ12859MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ4631MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ9115MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ10479MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ1390MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ10597MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY3300054
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW